Abstract: Objective  To evaluate the prognosis values of modified Gustave Roussy Immune Score (mGRIm-Score) for patients with unresectable esophageal squamous cell carcinoma (ESCC). Methods The data on lactic dehydrogenase, neutrophil/lymphocyte ratio and serum albumin of 150 patients with unresectable ESCC before chemoradiotherapy were collected . The optimal cut-off values were calculated by receiver operating characteristic(ROC) curves and the mGRIm-Score was constructed. The patients were divided into high mGRIm-Score group and low mGRIm-Score group according to the scoring criteria. Survival was analyzed by Kaplan-Meier method, and independent prognostic factors were analyzed by multivariable Cox regression. Results The median overall survival for high mGRIm-Score group and low mGRIm-Score group were 17.0 months (95%CI: 9.6-24.4 months ) and 48.0 months(95%CI: 38.9-57.1 months), respectively; the median progression-free survival were 12.0 months(95%CI :9.5-14.5 months) and 25.0 months (95%CI: 15.7-52.4 months), respectively, and the differences were statistically significant(all P<0.05). Multivariable analysis suggested that mGRIm-Score was an independent prognostic factor for overall survival (HR=1.626, 95%CI :1.1-2.5, P=0.024) and progression-free survival (HR=1.539, 95%CI :1.0-2.3, P=0.034) . Conclusions The mGRIm-Score before chemoradiotherapy can be used as a comprehensive indicator to evaluate the survival prognosis of patients with unresectable ESCC.

Key words: Esophageal squamous cell carcinoma, Concurrent chemoradiotherapy, Modified Gustave Roussy Immune Score, Lactate dehydrogenase, Albumin, Neutrophil/lymphocyte ratio; , Prognosis